A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer

Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol
Autors principals: Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., Poirier, B.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2019
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6380645/
https://ncbi.nlm.nih.gov/pubmed/30853812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars